

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative and rare disease pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading prescription products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Medexus to Participate in Two Upcoming Virtual Investor Conferences

Dec 2 2021, 4:15 PM EST

Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac's Type A Meeting with FDA on Treosulfan

Dec 2 2021, 8:08 AM EST

Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021

Nov 10 2021, 5:00 PM EST

Investor Relations

Crescendo Communications, LLC
David Waldman / Natalya Rudman
T: 212-671-1020
mdp@crescendo-ir.com

Management Team

Ken d'Entremont

Chief Executive Officer and Director

Marcel Konrad

Chief Financial Officer

Michael Adelman

General Manager, U.S. Operations

Michael Pine

Senior Vice President of Business Development and Strategy

Richard Labelle

Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations

Kerry Bakewell

Vice President Specialty Markets, Canadian Operations

Medexus Pharmaceuticals, Inc.

35 Nixon Rd Unit 1
Bolton, ON L7E 1K
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.